AU2002342238B2 - 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor - Google Patents

1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor Download PDF

Info

Publication number
AU2002342238B2
AU2002342238B2 AU2002342238A AU2002342238A AU2002342238B2 AU 2002342238 B2 AU2002342238 B2 AU 2002342238B2 AU 2002342238 A AU2002342238 A AU 2002342238A AU 2002342238 A AU2002342238 A AU 2002342238A AU 2002342238 B2 AU2002342238 B2 AU 2002342238B2
Authority
AU
Australia
Prior art keywords
compound
oxa
benzoyl
undecan
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002342238A
Other languages
English (en)
Other versions
AU2002342238A1 (en
Inventor
Hai-Ying Cai
Michael Patrick Dillon
Guido Galley
Annick Goergler
Sabine Kolczewski
Dawn Marie Muszynski-Barsy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2002342238A1 publication Critical patent/AU2002342238A1/en
Application granted granted Critical
Publication of AU2002342238B2 publication Critical patent/AU2002342238B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2002342238A 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor Ceased AU2002342238B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
EP01111644.9 2001-05-14
PCT/EP2002/004935 WO2002092604A1 (en) 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Publications (2)

Publication Number Publication Date
AU2002342238A1 AU2002342238A1 (en) 2003-05-01
AU2002342238B2 true AU2002342238B2 (en) 2007-01-25

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002342238A Ceased AU2002342238B2 (en) 2001-05-14 2002-05-06 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor

Country Status (17)

Country Link
US (1) US6599900B2 (enExample)
EP (1) EP1390372B1 (enExample)
JP (1) JP4056887B2 (enExample)
KR (1) KR100618063B1 (enExample)
CN (1) CN1264847C (enExample)
AR (1) AR033631A1 (enExample)
AT (1) ATE401333T1 (enExample)
AU (1) AU2002342238B2 (enExample)
BR (1) BR0209604A (enExample)
CA (1) CA2447329C (enExample)
DE (1) DE60227657D1 (enExample)
DK (1) DK1390372T3 (enExample)
ES (1) ES2310206T3 (enExample)
MX (1) MXPA03010321A (enExample)
PT (1) PT1390372E (enExample)
WO (1) WO2002092604A1 (enExample)
ZA (1) ZA200308535B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554671A1 (en) 2004-02-10 2005-08-18 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
UA90708C2 (ru) 2005-02-25 2010-05-25 Ф. Хоффманн-Ля Рош Аг Таблетки с улучшенной дисперсностью лекарственного вещества
EA012421B1 (ru) * 2005-03-03 2009-10-30 Янссен Фармацевтика Н. В. Замещённые производные оксадиазаспиро[5.5]ундеканона и их применение в качестве антагонистов нейрокинина
CN101137657B (zh) 2005-03-08 2011-02-02 詹森药业有限公司 作为神经激肽（nk1）拮抗剂的二氮杂-螺-[4.4]-壬烷衍生物
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
BRPI0809646A2 (pt) 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
CN107849017B (zh) 2015-07-31 2021-03-30 辉瑞公司 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
AU2018208846A1 (en) 2017-01-20 2019-07-25 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
WO2018134698A1 (en) 2017-01-23 2018-07-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation

Also Published As

Publication number Publication date
PT1390372E (pt) 2008-08-25
CN1507449A (zh) 2004-06-23
CA2447329C (en) 2009-07-28
DE60227657D1 (de) 2008-08-28
CA2447329A1 (en) 2002-11-21
CN1264847C (zh) 2006-07-19
JP2004534758A (ja) 2004-11-18
EP1390372B1 (en) 2008-07-16
BR0209604A (pt) 2004-03-23
ES2310206T3 (es) 2009-01-01
AR033631A1 (es) 2003-12-26
US20030004163A1 (en) 2003-01-02
WO2002092604A1 (en) 2002-11-21
ATE401333T1 (de) 2008-08-15
US6599900B2 (en) 2003-07-29
KR20030094405A (ko) 2003-12-11
MXPA03010321A (es) 2004-02-17
DK1390372T3 (da) 2008-09-15
KR100618063B1 (ko) 2006-08-30
ZA200308535B (en) 2005-01-31
JP4056887B2 (ja) 2008-03-05
EP1390372A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
CA2411716C (en) 1,3,8-triaza-spiro [4.5] decan derivatives
CN115279370B (zh) 用于brd9的靶向降解的化合物
JP7692362B2 (ja) Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬
US7247628B2 (en) Cannabinoid receptor ligands and uses thereof
AU2001267513A1 (en) 1,3,8-triaza-spiro'4,5!decan-4-one derivatives as neurokinin receptor antagonists
AU2002342238B2 (en) 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
EP3858835A1 (en) Pyrimidine-based antiproliferative agents
CN119137124A (zh) 杂环glp-1激动剂
CA3048376A1 (en) Bmp-signal-inhibiting compound
JP2011507824A (ja) アンドロゲン受容体関連状態の治療に使用の二環系誘導体
BR112020018983A2 (pt) Inibidores de canal receptor de potencial transitório de oxadiazol
TWI614244B (zh) 吲哚啉-２-酮衍生物
EA009742B1 (ru) Соединения бициклических пиразолила и имидазолила и их применение
AU2002342238A1 (en) 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
JP3287577B2 (ja) １，２，３，４―テトラヒドロ―ベンゾフロ［３，２―ｃ］ピリジン誘導体
US20230099441A1 (en) Heterocyclic compound, application thereof, and composition containing same
JP4751398B2 (ja) ハロゲン置換ベンゾジアゼピン誘導体
JP2008521771A (ja) 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体
JP2002348289A (ja) ３環性複素環化合物、その製造法および用途
TW202142538A (zh) 雜環ｇｌｐ－１促效劑
HK1141024A (en) Pyrimido [4,5-d] azepine derivatives as 5-ht2c agonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired